However, EGFR-TKI treatment for breast cancer has been evaluated in clinical trials, but the trials are currently underwhelming (19, 20), and there is still no available clinical drug targeting EGFR to inhibit TNBC metastasis. This evidence concerns the gene EGFR and breast cancer.